Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Shares Traded Last Trade
  -25.00p -0.55% 4,560.00p 16,797 15:50:34
Bid Price Offer Price High Price Low Price Open Price
4,550.00p 4,570.00p 4,585.00p 4,350.00p 4,585.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.58 -39.64 -31.84 3,033.9

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
16/8/201812:11(Chi-Med)Hutchinson China Meditech Limited1,585
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 4,585p.
Hutchison China Meditech has a 4 week average price of 4,350p and a 12 week average price of 4,050p.
The 1 year high share price is 5,920p while the 1 year low share price is currently 3,590p.
There are currently 66,532,683 shares in issue and the average daily traded volume is 10,039 shares. The market capitalisation of Hutchison China Meditech is £3,033,890,344.80.
lauders: The sudden weakness is probably a combination of two things: 1) The vaccine issue that is rocking China: 2) The likelihood of no news for a few months post the results release. May be time to top-up if the fall becomes overdone. Seems that the US dictates the share price direction these days.
nimrod22: should be seen as a buying opportunity while the share price is slopping around at low volume.
nimrod22: I did wonder if the share price may have suffered because it has "China" in the company name and the frequent news about tariffs?? For anybody following Chinese based shares.. Xiaomi on the Hong Kong board is worth a punt, IPO last Monday at low end of valuation of 17HK$, dropped and since recovered to 21.45HK$. Will also be listed on the Hang Seng index on 23rd July. Plenty of info out there.
steeplejack: Luckily,management have been awarded new options at a strike price that reflects recent share price weakness.Every cloud has a silver lining.
lauders: You could say that gswredland: Https:// Don't think anything has been sold other than when it went above 10% of portfolio value and then it had to be for balancing. Think that is correct. What's up with today's share price action? Good news and negative. Should have released it as an RNS and not RNSNON! Perhaps the US market will appreciate it?
nerdofsteel: What I can say is that when someone buys ADR's or AIM shares marketmakers sometimes make trades between the 2 types of securities to true up the books - there is an explanation about this on the Company's website. The recent drop in the valuation of sterling has helped driveLondon share price, although I agree that there is a disparity. Over the last 2 years occasionally the disparity has been quite large but always comes back into line on a fairly regular basis, helped by the true-up.
nerdofsteel: I notice we are in the Investors Chronicle AIM top 10 picks for 2018 4. Hutchison China MediTech It has been 30 years since a Chinese company last launched a globally commercialised medicine, but Hutchison China Meditech (HCM) is on the cusp of changing that. Its novel cancer drug, Savolitinib, is in the closing stages of a final phase clinical trial which analysts think has a 75 per cent chance of success. If it gets the green light from regulators, Savolitinib will be used to treat kidney cancer, while further testing might give it the potential to be used in non-small cell lung cancer patients as well. After 20 years of steady investment in research and development, clinical success has come thick and fast in the last 18 months. Aside from the Savolitinib trial, Chi-Med has seven final phase programmes ongoing in four different drugs which analysts think could generate peak annual sales of $7.6bn. The most advanced of these is colorectal cancer treatment, Fruquintinib, which could be launched in China later this year. Arguably more important is the depth in the early- and mid-stage pipeline, which gives the group an excellent long-term outlook. There are five oncology medicines currently undergoing early-stage human trials, which should be launched between 2020 and 2023 and a further five in pre-clinical studies. Chi-Med is certainly not a one-trick pony looking to develop and divest novel drugs, but a fast-growing commercial biotech company with a long line of new medicines which should keep the top line growing for many years. The group£s commercial arm in China is well established and will provide an excellent platform to sell medicines once they gain approval. It also generates cash to fund the drug development branch, while a recent $293m fundraise from the group£s Nasdaq investors has strengthened the balance sheet. The innovation division also earns money for Chi-Med in the form of milestone payments, notably from big pharma groups Eli Lilly and AstraZeneca, which the group has partnered with to develop Fruquintinib and Savolitinib, respectively. The group will continue to receive one-off payments throughout the development stage and then royalties on the drugs£ sales. Profits may still be some way off (which makes valuing Chi-Med very difficult), but we think the plethora of potential drug launches should give plenty of firepower to the share price in the next few years. The Chinese healthcare market is also becoming increasingly attractive as doctors and pharma companies seek to match their western counterparts. Buy. MB
dbadvn: Had a very interesting meeting with the CFO . They are certainly sticking to plan and gearing up for European/US sales independently of whatever happens with Lilley etc. Making all the right noises on Clinical/ Sales teams/ Branding/ Competition and realistic on timescale. Not defending the fact that the recent cash raise was basically opportunistic use of perfect market conditions . Looking to be cash flow positive within 5 years ( doe not exclude more cash raising depending on opportunities). The positive "elephant in the room" is the $50bn potential of HMPL 523 in the immunology market. Although still at the early stages HCM seem to have the lead here and only Gilead as competition. Short term lack of news flow may see the share price drift but medium and long term potential probabilities of success are increasing . At some point the US market will start to valur HCM in the same way as the US Biotechs ( less the takeover premium perhaps ) .At that point the share price will react strongly . When that happens is anyones guess so I for one am staying invested long term
nerdofsteel: mad - agree 100%, and if you look back at the share price in London over the last 10 years you see sometimes quite lengthy periods where the share price is stagnant, followed by sharp increases, then further stagnation
lauders: Thank you Nerdofsteel. Appreciate the feedback. Your reply makes sense, so it could be a win-win. If positive the share price will likely increase in turn, if negative it will drop but allow those with the future in mind to add more and benefit from marketing freely and perhaps penning an alternative deal. Can Lilly risk the latter? Now let's just see what the Nasdaq does today. If it is a good day the share price will recover. If not we could be going down again.
Hutchison China Meditech share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180816 17:37:51